NYSE to Commence Delisting Proceedings Against Natuzzi S.p.A. (NTZ)

NEW YORK--(BUSINESS WIRE)-- The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the American Depositary Shares (“ADSs”), each representing five Ordinary Shares of Natuzzi S.p.A. (the “Company”) — ticker symbol NTZ — from the NYSE. Trading in the Company’s ADSs will be suspended immediately.

NYSE Regulation reached its decision to delist the Company’s ADSs pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.

The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the U.S Securities and Exchange Commission to delist the Company’s ADSs upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260826769948/en/

Company Contact:
Group CFO | Carlo Silvestri | [email protected]
Chief Auditor - Global Internal Audit | Pierluigi Binetti | [email protected]
Natuzzi Investor Relations | Piero Direnzo | [email protected]

Natuzzi Corporate Communication
Giancarlo Renna | Communication Manager | [email protected]
Barbara Colapinto | [email protected]

NYSE Contact:
NYSE Communications
[email protected]

Source: NYSE Regulation

You May Also Be Interested In

• Franklin Templeton Announces Distributions for Certain Closed-End Funds Pursuant to their Managed Distribution Policy for the Months of October, November and December 2026
• Keysight Expands Active and Passive 1.6T Copper Interconnect Validation for Scale-Out Data Centers
• Cyted Health Announces Positive U.S. Clinical Validation Data for the EndoSign® Barrett’s Esophagus Test